Lee Anderson joins Biofidelity to expand the adoption of ASPYRE-Lung, a completely new category of molecular diagnostic that fulfills an acute unmet clinical need for people with non-small cell lung cancer and the clinicians who treat them
CAMBRIDGE, UK and RESEARCH TRIANGLE PARK, NORTH CAROLINA, USA, October 17, 2024 - Biofidelity, a revolutionary genomic technology company, today announced the appointment of Lee Anderson as Chief Commercial Officer. With more than 30 years of expertise in biotechnology and diagnostic oncology, Lee brings a wealth of experience from several start-up companies and successful new product launches.
“We are excited to welcome Lee to Biofidelity during this pivotal time,” said Dr. Barnaby Balmforth, Co-Founder and CEO of Biofidelity. “His deep expertise in the oncology space and proven ability to lead high-performing commercial teams will be instrumental as we continue to push the boundaries of genomics and transform cancer care.”
Prior to joining Biofidelity, Lee spent 15 years at Genomic Health, where he helped launch Oncotype DX and served as Vice President of Sales and Global Customer Service. After Genomic Health’s acquisition by Exact Sciences, he led the commercial integration and later served as General Manager of the Precision Oncology business unit, overseeing new diagnostic product launches.
In addition to his corporate roles, Lee has served on the advisory board of Florida State College’s Department of Biological Sciences, contributing to the development of their Biomedical Science Degree program.
About Biofidelity
Biofidelity is a rapidly growing commercial-stage genomic technology company dedicated to improving and extending the lives of patients with cancer by enabling better targeting of therapies, early detection of treatment resistance and routine monitoring of treatment response. Visit biofidelity.com and connect with us on LinkedIn and X.
Contact
Andrea Conners
+1 239-828-1202
a.conners@biofidelity.com